# Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication

> **NCT06886620** · PHASE3 · TERMINATED · sponsor: **Genovate Biotechnology Co., Ltd.,** · enrollment: 14 (actual)

## Conditions studied

- Intermittent Claudication

## Interventions

- **DRUG:** Cilostazol 200 mg
- **DRUG:** Cilostazol 100 mg

## Key facts

- **NCT ID:** NCT06886620
- **Lead sponsor:** Genovate Biotechnology Co., Ltd.,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-14
- **Primary completion:** 2017-02-08
- **Final completion:** 2017-02-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886620, "Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06886620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*